Swiss Life Asset Management’s Blueprint Medicines BPMC Stock Holding History

Swiss Life Asset Management’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-1,638	Closed	-$210K	–	1194
2025 Q2	$210K	Buy	+1,638	New	+$170K	﹤0.01%	809

Other funds holding BPMC

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Swiss Life Asset Management's BPMC Position: Q3 2025 in Review

Swiss Life Asset Management sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 1,638 shares — an estimated $210K sold.

Swiss Life Asset Management first reported a position in BPMC in Q2 2025 and held it in 1 quarter. The position peaked at $210K in Q2 2025. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

Swiss Life Asset Management reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
Swiss Life Asset Management sold 1,638 Blueprint Medicines shares in Q3 2025, an estimated $210K.
Swiss Life Asset Management first reported a position in Blueprint Medicines in Q2 2025 and held it in 1 quarter.
Swiss Life Asset Management's Blueprint Medicines position peaked at $210K in Q2 2025.
5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on Swiss Life Asset Management's 13F filing for Q3 2025, filed 2 Dec 2025.